Join to View Full Profile
2139 Tysons Executive CtDunn Loring, VA 22027
Phone+1 703-849-8497
Are you Dr. Elkashef?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ahmed Elkashef, MD is a board certified psychiatrist in Dunn Loring, Virginia.
Education & Training
University of Maryland/Sheppard PrattResidency, Psychiatry, 1988 - 1990
Prisma Health/University of South Carolina SOM Columbia (Columbia)Residency, Psychiatry, 1986 - 1987
Cairo University School of MedicineClass of 1977
Certifications & Licensure
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 5 citationsA cholecystokinin B receptor antagonist and cocaine interaction, phase I studyAhmed Elkashef, James Robert Brašić, Louis R. Cantelina, Roberta Kahn, Nora Chiang
CNS Neuroscience & Therapeutics. 2019-01-01 - National Rehabilitation Center programme performance measures in the United Arab Emirates, 2013.Ahmed Elkashef, Layla Alhyas, Hanan Al Hashmi, Dina Mohammed, Alison Gonzalez
Eastern Mediterranean Health Journal = La Revue De Sante De La Mediterranee Orientale = Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2017-03-01 - 45 citationsBupropion for the Treatment of Methamphetamine Dependence in Non-Daily Users: a Randomized, Double-Blind, Placebo-Controlled TrialAnn L. Anderson, Shou Hua Li, Denka Markova, Tyson H. Holmes, Nora Chiang
Drug and Alcohol Dependence. 2015-05-01
Press Mentions
Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in ImmunocompetenceMay 7th, 2020
INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of NaloxoneDecember 18th, 2018
INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations Versus Intramuscular and Intravenous Naloxone for Opioid OverdoseNovember 1st, 2018
